Comparing Dare Bioscience (DARE) & The Competition

Dare Bioscience (NASDAQ:DARE) is one of 896 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Dare Bioscience to similar companies based on the strength of its risk, institutional ownership, analyst recommendations, profitability, earnings, dividends and valuation.

Profitability

This table compares Dare Bioscience and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	-803.80%	-748.30%	-38.75%
Dare Bioscience Competitors	-2,381.34%	-218.59%	-15.77%

Risk & Volatility

Dare Bioscience has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, Dare Bioscience’s rivals have a beta of -3.80, suggesting that their average stock price is 480% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Dare Bioscience and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1	0	3	0	2.50
Dare Bioscience Competitors	7803	13892	25799	1039	2.41

Dare Bioscience presently has a consensus price target of $5.00, indicating a potential upside of 624.64%. As a group, “Pharmaceuticals” companies have a potential upside of 25.26%. Given Dare Bioscience’s stronger consensus rating and higher probable upside, equities analysts plainly believe Dare Bioscience is more favorable than its rivals.

Insider & Institutional Ownership

6.7% of Dare Bioscience shares are owned by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 3.4% of Dare Bioscience shares are owned by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Dare Bioscience and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Dare Bioscience	$1.03 million	-$13.40 million	-0.99
Dare Bioscience Competitors	$3.54 billion	$3.16 billion	552.63

Dare Bioscience’s rivals have higher revenue and earnings than Dare Bioscience. Dare Bioscience is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Dare Bioscience rivals beat Dare Bioscience on 8 of the 13 factors compared.

Dare Bioscience Company Profile

Daré Bioscience, Inc. (NASDAQ: DARE) is a biopharmaceutical company focused on developing and commercializing therapies designed to address unmet needs in women’s health. The company’s research and development activities span contraception, vaginal health, sexual health and reproductive health, with an emphasis on pharmaceutical products and drug-delivery technologies. Daré’s lead commercial product is XACIATO (clindamycin phosphate) vaginal gel 2%, an FDA-approved prescription treatment for bacterial vaginosis in females 12 and older.